In-person visitor numbers rebound sharply, with record C-Suite attendance and the largest-ever online presence.     The global pharma industry was out in full force …

Phase 3 clinical trial focuses on adults with moderate-to-severe chronic hand eczema. LEO Pharma has announced positive results from its DELTA 1 trial – the …

The clinical trial has received regulatory approval and involves endometriosis candidate SN132D. Spago Nanomedical has announced that it has received regulatory approval to initiate a …

99% of participants retained very high neutralising antibody levels 12 months after treatment. Valneva has announced positive antibody persistence data twelve months for its chikungunya …

The therapy has reduced inflammation and supported the remodelling of damaged bone. Istesso – a London-based immunometabolism drug development company – has announced that the …

Children and adults have been treated using the Lyme disease antibody candidate VLA15 Pfizer has reported antibody persistence data six months after the completion of …

Positive scientific opinion by EMA would create a pathway for arpraziquantel in African endemic countries. Merck KGaA (Merck) – known as EMD Serono in the …

The project involves 27 partners including patient associations, hospitals and universities. Almirall – a company focused on skin health – is participating in Facilitate, a …

C4XD will receive milestone payments worth up to $16m ahead of the first clinical trial. C4XD – a company focused on drug discovery – has …

Treatment involves adults with certain forms of advanced stomach and oesophageal cancer. Bristol Myers Squibb (BMS) has announced that the National Institute for Health and …